Due to a substantial overlap in clinical and radiological presentations between MOG-EM and other acquired demyelinating CNS disorders, deciding which clinical and paraclinical findings should be accompanied by MOG-IgG testing, especially at first clinical presentation, remains an evolving challenge. This evidence concerns the gene MOG and central nervous system disorder.